• Offer supports access for eligible patients without insurance to FDA-approved Ozempic^® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, the GLP-1 medicine with the broadest range of FDA-approved indications for adults with type 2 diabetes¹
• For the first time, Ozempic^® is available via home delivery through NovoCare^® Pharmacy. Patients using traditional pharmacies can also access the offer through multiple ways including Ozempic.com and NovoCare.com
• GoodRx is offering all strengths of Ozempic^® and Wegovy^® pens to eligible self-paying patients for $499-per-month, accessible at more than 70,000 pharmacies nationwide

Novo Nordisk announced the launch of a new offer that enables self-paying, eligible, type 2 diabetes patients access to authentic, FDA-approved Ozempic^® (semaglutide) for $499 per month, as part of the company's ongoing effort to explore new collaborations and approaches to improving access to authentic semaglutide medicines. This offer is available through multiple platforms to eligible patients with a prescription for Ozempic^® and aims to assist type 2 diabetes patients who may potentially face prices at or above wholesale cost that are uninsured or choose to self-pay.

"Improving access to our authentic FDA-approved treatments is central to our mission at Novo Nordisk. While Ozempic^® is well covered in the US, let's not forget that there are some patients who pay out-of-pocket for this vital medicine. We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that's one too many," said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. "This is why we felt it was important to make Ozempic^®, the GLP-1 with the broadest range of FDA-approved indications for adults with type 2 diabetes, more affordable to those without insurance who deserve the real thing."